Highlights of SAB BIO's Recent Presentations at EASD
-As SAB initiates its Phase 2b SAFEGUARD study for SAB-142, it has used the EASD platform to engage with prominent T1D thought leaders for collaboration and support-
-Recent data presented at EASD reinforces SAB-142’s potential as a transformative immunotherapeutic for Type 1 Diabetes (T1D)-
MIAMI -- SAB Biotherapeutics, Inc. (NASDAQ: SABS), a clinical-stage biopharmaceutical company, has been making waves in the realm of autoimmune diseases with its innovative research into human anti-thymocyte immunoglobulin (ATG). The company's mission centers on delaying the onset or progression of T1D. At the recent EASD Annual Meeting, which showcased its wide array of diabetes research, SAB highlighted multiple key presentations that promise to reshape T1D therapy.
During the conference, SAB delivered four oral presentations and participated in an invited discussion at an INNODIA symposium. Samuel J. Reich, Chairman and CEO of SAB BIO, expressed pride in presenting the data from their comprehensive findings regarding SAB-142, a fully human anti-thymocyte IgG, specifically aimed at new-onset Stage 3 T1D patients in their Phase 2b SAFEGUARD clinical study.
Significant Presentation Highlights
SAB's presentations offered tremendous insights, particularly from Dr. Alexandra Kropotova, the Executive Vice President and Chief Medical Officer. At the INNODIA-hosted symposium, Dr. Kropotova discussed the considerable potential of unique disease-modifying therapies aimed at T1D patients. Her follow-up presentation focused on the groundbreaking details regarding the mechanism of action of SAB-142. Within these discussions, she emphasized that SAB-142 not only exhibits a clinically validated and multi-specific mechanism of action, but it also maintains continuous immunomodulation, avoiding the sustained lymphodepletion seen in other treatments like rabbit ATG.
According to the data from a Phase 1 clinical study involving 68 participants, SAB-142 demonstrates the ability to support an enhanced immune response without compromising T-cell levels significantly. This pioneering approach suggests a new trajectory for the immunotherapy landscape focused on T1D.
Pharmacokinetic Insights from SAB-142
Further affirming the promise of SAB-142, Eric Sandhurst, Ph.D., the Director of Program Management at SAB BIO, presented novel pharmacokinetic data. Utilization of a unique pharmacokinetic assay revealed that SAB-142 maintains a dose-proportional profile and exhibits a reproducible pharmacokinetic behavior. These results are crucial as they highlight the treatment's favorable short pharmacokinetic profile while sustaining immunomodulatory effects well beyond Day 120 after administration.
Industry Impact and Collaborations
Engagements at the EASD Annual Meeting allowed SAB to solidify alliances with pivotal patient advocacy groups, principal investigators, and influential experts in the field. This networking is fundamental as SAB aims to enhance its clinical study’s success through these collaborations.
Related Research Findings
In conjunction with SAB’s presentations, the results of the INNODIA-sponsored MELD-ATG study underscored the considerable disease-modifying potential of rabbit ATG treatments in Stage 3 T1D patients. The study achieved significant preservation of C-peptide levels at 12 months while demonstrating substantial improvements in metabolic outcomes, namely HbA1C, establishing a benchmark for current and future treatments.
Mr. Reich commented on these findings, expressing optimism about the significant therapeutic benefits that this class of treatment may have for individuals newly diagnosed with T1D. He notes that these findings enhance their confidence in preferring SAB-142 as a forward-thinking alternative with potentially improved safety and re-dosing capabilities.
SAB's partnership with INNODIA reinforces its commitment to pioneering advanced therapies in Europe. INNODIA’s collaborations across leading T1D centers pave the way for significant advancements in the ongoing Phase 2b clinical studies for SAB-142.
About SAB BIO
SAB BIO is at the forefront of developing inventive solutions to combat T1D through its multi-specific, high-potency immunoglobulins (IgGs). With a focus on eliminating the need for human donors, SAB utilizes transgenic technology to create a leading-edge repertoire of human IgGs tailored to meet the unmet medical needs in autoimmune disorders. SAB-142 stands as a beacon in this endeavor, designed to extend and potentially alter the landscape of treatment for T1D patients.
Frequently Asked Questions
What is SAB-142?
SAB-142 is a fully human anti-thymocyte IgG developed by SAB BIO aimed at treating new-onset Stage 3 autoimmune T1D patients.
What were the key findings from SAB BIO's presentations at EASD?
Findings highlighted the mechanisms of SAB-142, the importance of its pharmacokinetic profile, and the positive data from ongoing clinical studies.
How does SAB-142 differ from other treatments?
SAB-142 avoids sustained lymphodepletion, a common side effect associated with other treatments such as rabbit ATG.
What is the connection between SAB BIO and INNODIA?
SAB collaborates closely with INNODIA to advance the development of innovative therapies in T1D, supporting clinical studies with leading researchers.
Why is the MELD-ATG study significant?
The MELD-ATG study validates the disease-modifying potential of rabbit ATG in T1D, demonstrating significant metabolic and clinical benefits that support ongoing immunotherapy advancements.
